Nanoform Finland Plc announced a strategic partnership whereby CBC Co. Ltd., will utilize its extensive experience in the Japanese pharmaceutical industry to identify opportunities for Nanoform's cutting-edge nanomedicine engineering technologies. Nanoformed medicines have been shown to overcome innovators' drug bioavailability issues and reduce dose size and pill burden to improve patient-acceptance, both for new drugs and reformulations of existing products.

Nanoform technology has been effective in several in vitro and in vivo studies across multiple routes of administration including oral, inhaled, ophthalmic and injectables, and across multiple molecule types such as enzalutamide and many other molecules. The partnership commences immediately, and the companies have planned several joint activities to introduce their collaboration, including representation of Nanoform by CBC at CPHI Japan, which takes place at Tokyo Big Sight, Tokyo, from April 17-19, 2024.